Abstract
Background:
Hypothalamic obesity is a devastating consequence of craniopharyngioma. Bariatric surgery could be a promising therapeutic option. However, its efficacy and safety in patients with craniopharyngioma-related hypothalamic obesity remain largely unknown.
Objectives:
We investigated the efficacy of bariatric surgery for inducing weight loss in patients with craniopharyngioma-related hypothalamic obesity. In addition, we studied the safety of bariatric surgery regarding its effects on hormone replacement therapy for pituitary insufficiency.
Methods:
In this retrospective matched case–control study, we compared weight loss after bariatric surgery (that is, Roux-en-Y gastric bypass and sleeve gastrectomy) between eight patients with craniopharyngioma-related hypothalamic obesity and 75 controls with ‘common’ obesity during 2 years of follow-up. We validated our results at 1 year of follow-up in a meta-analysis. In addition, we studied alterations in hormone replacement therapy after bariatric surgery in patients with craniopharyngioma.
Results:
Mean weight loss after bariatric surgery was 19% vs 25% (difference −6%, 95% confidence of interval (CI) −14.1 to 4.6; P=0.091) at 2 years of follow-up in patients with craniopharyngioma-related hypothalamic obesity compared with control subjects with ‘common’ obesity. Mean weight loss was 25% vs 29% (difference −4%, 95% CI −11.6 to 8.1; P=0.419) after Roux-en-Y gastric bypass and 10% vs 20% (difference −10%, 95% CI −14.1 to −6.2; P=0.003) after sleeve gastrectomy at 2 years of follow-up in patients with craniopharyngioma-related hypothalamic obesity vs control subjects with ‘common’ obesity. Our meta-analysis demonstrated significant weight loss 1 year after Roux-en-Y gastric bypass, but not after sleeve gastrectomy. Seven patients with craniopharyngioma suffered from pituitary insufficiency; three of them required minor adjustments in hormone replacement therapy after bariatric surgery.
Conclusions:
Weight loss after Roux-en-Y gastric bypass, but not sleeve gastrectomy, was comparable between patients with craniopharyngioma-related hypothalamic obesity and control subjects with ‘common’ obesity at 2 years of follow-up. Bariatric surgery seems safe regarding its effects on hormone replacement therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Muller HL . Craniopharyngioma. Endocr Rev 2014; 35: 513–543.
Olsson DS, Andersson E, Bryngelsson IL, Nilsson AG, Johannsson G . Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab 2015; 100: 467–474.
Muller HL, Faldum A, Etavard-Gorris N, Gebhardt U, Oeverink R, Kolb R et al. Functional capacity, obesity and hypothalamic involvement: cross-sectional study on 212 patients with childhood craniopharyngioma. Klinische Padiatrie 2003; 215: 310–314.
Muller HL, Gebhardt U, Etavard-Gorris N, Korenke E, Warmuth-Metz M, Kolb R et al. Prognosis and sequela in patients with childhood craniopharyngioma—results of HIT-ENDO and update on KRANIOPHARYNGEOM 2000. Klinische Padiatrie 2004; 216: 343–348.
Roth CL . Hypothalamic obesity in craniopharyngioma patients: disturbed energy homeostasis related to extent of hypothalamic damage and its implication for obesity intervention. J Clin Med 2015; 4: 1774–1797.
Haslam DW, James WP . Obesity. Lancet 2005; 366: 1197–1209.
Muller HL, Bueb K, Bartels U, Roth C, Harz K, Graf N et al. Obesity after childhood craniopharyngioma—German multicenter study on pre-operative risk factors and quality of life. Klinische Padiatrie 2001; 213: 244–249.
Muller HL . Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity. Curr Opin Endocrinol Diabetes Obes 2016; 23: 81–89.
Roemmler-Zehrer J, Geigenberger V, Stormann S, Ising M, Pfister H, Sievers C et al. Specific behaviour, mood and personality traits may contribute to obesity in patients with craniopharyngioma. Clin Endocrinol 2015; 82: 106–114.
Muller HL, Emser A, Faldum A, Bruhnken G, Etavard-Gorris N, Gebhardt U et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab 2004; 89: 3298–3305.
Roth CL, Eslamy H, Werny D, Elfers C, Shaffer ML, Pihoker C et al. Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity 2015; 23: 1226–1233.
Rakhshani N, Jeffery AS, Schulte F, Barrera M, Atenafu EG, Hamilton JK . Evaluation of a comprehensive care clinic model for children with brain tumor and risk for hypothalamic obesity. Obesity 2010; 18: 1768–1774.
Sjostrom L . Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219–234.
Inge TH, Pfluger P, Zeller M, Rose SR, Burget L, Sundararajan S et al. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract 2007; 3: 606–609.
Padwal R, Brocks D, Sharma AM . A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010; 11: 41–50.
Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M . Drug disposition in obesity: toward evidence-based dosing. Ann Rev Pharmacol Toxicol 2015; 55: 149–167.
Wolf P, Winhofer Y, Smajis S, Kruschitz R, Schindler K, Gessl A et al. Hormone substitution after gastric bypass surgery in patients with hypopituitarism secondary to craniopharyngioma. Endocr Pract 2016; 22: 595–601.
Hedenbro JL, Naslund E, Boman L, Lundegardh G, Bylund A, Ekelund M et al. Formation of the Scandinavian Obesity Surgery Registry, SOReg. Obesity Surgery 2015; 25: 1893–1900.
Bretault M, Boillot A, Muzard L, Poitou C, Oppert JM, Barsamian C et al. Clinical review: bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis. J Clin Endocrinol Metab 2013; 98: 2239–2246.
Higgins JP, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. Brit Med J 2003; 327: 557–560.
Weismann D, Pelka T, Bender G, Jurowich C, Fassnacht M, Thalheimer A et al. Bariatric surgery for morbid obesity in craniopharyngioma. Clin Endocrinol 2013; 78: 385–390.
Madsbad S, Dirksen C, Holst JJ . Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet 2014; 2: 152–164.
Coomans CP, van den Berg SA, Lucassen EA, Houben T, Pronk AC, van der Spek RD et al. The suprachiasmatic nucleus controls circadian energy metabolism and hepatic insulin sensitivity. Diabetes 2013; 62: 1102–1108.
Rao RS . Bariatric surgery and the central nervous system. Obesity Surgery 2012; 22: 967–978.
Fierabracci P, Martinelli S, Tamberi A, Piaggi P, Basolo A, Pelosini C et al. Weight loss and variation of levothyroxine requirements in hypothyroid obese patients after bariatric surgery. Thyroid 2016; 26: 499–503.
Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol 2004; 61: 367–375.
Acknowledgements
We would like to thank the bariatric surgical teams of the Maasstad Ziekenhuis and Sint Franciscus Gasthuis (Rotterdam, the Netherlands), as well as the bariatric surgical teams of the Carlanderska Sjukhuset and Sahlgrenska University Hospital (Gothenburg, Sweden).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Wijnen, M., Olsson, D., van den Heuvel-Eibrink, M. et al. Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case–control study with 2 years of follow-up. Int J Obes 41, 210–216 (2017). https://doi.org/10.1038/ijo.2016.195
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2016.195
This article is cited by
-
Update on management of craniopharyngiomas
Journal of Neuro-Oncology (2022)
-
Five-Year Changes in Weight and Diabetes Status After Bariatric Surgery for Craniopharyngioma-Related Hypothalamic Obesity: a Case–Control Study
Obesity Surgery (2022)
-
Obesità post-neurochirurgia ipotalamica
L'Endocrinologo (2021)
-
Bariatric Surgery for Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy: a Matched Case–Control Study
Obesity Surgery (2020)
-
Craniopharyngioma
Nature Reviews Disease Primers (2019)